VIENNA, Austria – December 2017: At the reconvened sixtieth session of the Commission on Narcotic Drugs (CND) from 7 to 8 December 2017, the World Health Organization (WHO) announced the scheduling recommendations on psychoactive substances reviewed at the 39th meeting of the WHO Expert Committee on Drug Dependence (ECDD) held in Geneva from 6 to 10 November 2017. In total, 16 substances were critically reviewed by the ECDD and 12 substances were recommended for scheduling:

Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol:

Ocfentanil - Schedule I
Furanylfentanyl (Fu-F) - Schedule I
Acryloylfentanyl (Acrylfentanyl) - Schedule I
4-fluoroisobutyrfentanyl (para-Fluoroisobutyrfentanyl, 4-FIBF, pFIBF) - Schedule I
Tetrahydrofuranylfentanyl (THF-F) - Schedule I
Carfentanil - Schedule I and Schedule IV

Convention on Psychotropic Substances of 1971:

4-fluoramphetamine (4-FA) - Schedule II
AB-PINACA - Schedule II
AB-CHMINACA - Schedule II
5F-PB-22 - Schedule II
UR-144 - Schedule II
5F-ADB (5F-MDMB-PINACA) - Schedule II

The WHO recommended extracts or preparations containing almost exclusively cannabidiol (CBD) for critical review at the fortieth ECDD meeting on cannabis, and pregabalin and tramadol for critical review at the following ECDD meeting. Etizolam was recommended for surveillance.

For more information, please see:

List of psychoactive substances to be reviewed by the 39th Expert Committee on Drug Dependence
http://www.who.int/medicines/access/controlled-substances/substances-to-considered_at39thECDD.pdf?ua=1